New PKU drug AG-181 enters early human safety testing
Disease control
Recruiting now
This early-stage study tests a new drug called AG-181 in 20 adults with phenylketonuria (PKU), a genetic condition that causes high levels of phenylalanine in the blood. The main goal is to check if the drug is safe and tolerable. Researchers will also measure how the drug moves …
Phase: PHASE1 • Sponsor: Agios Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 11, 2026 20:51 UTC